Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease

Background: Alzheimer's disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon®, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Davide V Moretti, giuliano eBinetti, orazio eZanetti, giovanni b Frisoni
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2014-07-01
coleção:	Frontiers in Aging Neuroscience
Assuntos:	Dementia Alzheimer's disease EEG Cognitive Function oral rivastigmine transdermal rivastigmine
Acesso em linha:	http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00179/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!